Publications by authors named "Lucia Andras"
Objectives: Anti-drug antibodies (ADA) are responsible for decreased adalimumab efficacy in axial spondyloarthritis (SpA). We aimed to evaluate the ability of methotrexate (MTX) to decrease adalimumab immunisation.
Methods: A total of 110 patients eligible to receive adalimumab 40 mg subcutaneously (s.
Article Synopsis
- The study examined the survival rates of a second TNF inhibitor (TNFi) in patients with spondyloarthritis (SpA), noting that many patients stop their first TNFi within two years, but there are no clear guidelines for choosing a second one.
- 244 SpA patients were followed over several years, revealing that the average duration for the first TNFi was significantly longer than for the second (21.7 months vs. 15.4 months), and switching between different types of TNFi did not impact drug survival.
- Factors linked to better retention of the second TNFi included being male and being diagnosed with SpA at an age younger than 41, with age remaining a significant factor
Objective: To assess the implementation of European recommendations for use of TNF inhibitors for spondyloarthritis (SpA), rheumatologists' level of knowledge of and adherence to the recommendations, and potential barriers to the application of recommendations.
Methods: We conducted a retrospective study among 42 rheumatologists who initiated a first subcutaneous TNF inhibitor for SpA in 2013 or 2014. Thirty items from national and international recommendations were separated into 3 domains: indication, pretherapeutic monitoring, and management under TNF inhibitors.